Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KRAS | P01116 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2012738 | 0.87 | L3MBTL1 (0.48) | L3MBTL1KRASLMNAHTR6ALDH1A1 | |
| SCHEMBL29754156 | 0.83 | HTR6 (0.46) | L3MBTL1KRASLMNAHTR6SMN1; SMN2 | |
| SCHEMBL1846302 | 0.83 | HTR6 (0.46) | L3MBTL1KRASLMNAHTR6SMN1; SMN2 | |
| SCHEMBL15059343 | 0.82 | KRAS (0.48) | L3MBTL1KRASLMNAHTR6SMN1; SMN2 | |
| SCHEMBL18555717 | 0.82 | HTR6 (0.45) | L3MBTL1KRASLMNAHTR6SMN1; SMN2 | |
| SCHEMBL22128401 | 0.82 | L3MBTL1 (0.46) | L3MBTL1KRASLMNAHTR6ALDH1A1 | |
| SCHEMBL22128403 | 0.82 | L3MBTL1 (0.46) | L3MBTL1KRASLMNAHTR6ALDH1A1 | |
| SCHEMBL22128307 | 0.82 | L3MBTL1 (0.46) | L3MBTL1KRASLMNAHTR6ALDH1A1 | |
| SCHEMBL18546446 | 0.81 | HTR6 (0.44) | L3MBTL1KRASLMNAHTR6SMN1; SMN2 | |
| SCHEMBL30233593 | 0.80 | KMT2A (0.51) | L3MBTL1KRASLMNAHTR6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9364459-B2 | 3-(indolyl)- or 3-(azaindolyl)- 4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma | Johannes Gutenberg-Universität Mainz (DE) | 2016-06-14 | — | — | US | disclosed |
| EP-2512469-B1 | 3-(INDOLYL)-OR 3-(AZAINDOLYL)- 4-ARYLMALEIMIDE DERIVATIVES FOR USE IN THE TREATMENT OF COLON AND GASTRIC ADENOCARZINOMA | JOHANNES GUTENBERG UNIVERSITÄT MAINZ (DE) | 2016-03-02 | — | — | EP | disclosed |
| EP-2513089-B1 | 3-(INDOLYL)- OR 3-(AZAINDOLYL)-4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | JOHANNES GUTENBERG UNIVERSITÄT MAINZ (DE) | 2015-09-09 | — | — | EP | disclosed |
| US-9012659-B2 | 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment | Johannes Gutenberg—Universitat Mainz (DE) | 2015-04-21 | — | — | US | disclosed |
| US-20130131060-A1 | 3-(INDOLYL)- OR 3-(AZAINDOLYL)- 4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | Johannes Gutenberg-Universität Mainz (DE) | 2013-05-23 | — | — | US | disclosed |
| US-20130029986-A1 | 3-(INDOLYL)- OR 3-(AZAINDOLYL)- 4-ARYLMALEIMIDE DERIVATIVES FOR USE IN THE TREATMENT OF COLON AND GASTRIC ADENOCARZINOMA | UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ (DE) | 2013-01-31 | — | — | US | disclosed |
| EP-2343291-A1 | 3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment | Johannes Gutenberg-Universität Mainz (DE) | 2011-07-13 | — | — | EP | disclosed |
| EP-2338486-A1 | 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma | Johannes Gutenberg-Universität Mainz (DE) | 2011-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029986-A1 | 3-(INDOLYL)- OR 3-(AZAINDOLYL)- 4-ARYLMALEIMIDE DERIVATIVES FOR USE IN THE TREATMENT OF COLON AND GASTRIC ADENOCARZINOMA | SI, AADAC, INMT | L3MBTL1 2660/4885KRAS 450/4885LMNA 3284/4885 |
| US-20130131060-A1 | 3-(INDOLYL)- OR 3-(AZAINDOLYL)- 4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | IDH3A, INMT, IDH1 | L3MBTL1 755/4885KRAS 159/4885LMNA 3123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.